Cantor Fitzgerald resumed coverage on Zevra Therapeutics with a new price target

1/8/25 8:49:26 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Cantor Fitzgerald resumed coverage of Zevra Therapeutics with a rating of Overweight and set a new price target of $25.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ZVRA

Date	Price Target	Rating	Analyst
1/8/2025	$25.00	Overweight	Cantor Fitzgerald
10/7/2024	$20.00	Buy	Guggenheim
9/24/2024	$17.00	Mkt Outperform	JMP Securities
9/24/2024	$18.00 → $25.00	Buy	Maxim Group
4/2/2024	$12.00 → $18.00	Buy	Maxim Group
3/12/2024		Outperform	William Blair
3/17/2023	$12.00	Buy	Maxim Group